Induction Chemotherapy Followed by Radiotherapy in Patients with Cervical Lymph Node Metastases from Unknown Primary Carcinoma

被引:2
|
作者
Seol Y.M. [1 ]
Choi Y.J. [1 ]
Lee B.J. [2 ]
Wang S.G. [2 ]
机构
[1] Division of Hematology/Oncology, Department of Internal Medicine, Pusan National University Hospital, Medical Research Institute, Busan
[2] Department of Otolaryngology, Pusan National University Hospital, Medical Research Institute, Busan
关键词
Head and neck cancer; Induction chemotherapy; Lymph node metastasis; Unknown primary;
D O I
10.1007/s12070-014-0773-8
中图分类号
学科分类号
摘要
Cervical metastases from unknown primary tumors are rare and no clear therapeutic options are available. This study was performed to assess the efficacy and safety profiles of induction chemotherapy followed radiotherapy in patients with cervical lymph node metastases from unknown primary cancer. Patients with histological diagnosis of cervical lymph-node metastasis from carcinoma with an unknown primary cancer underwent induction chemotherapy followed by radiotherapy. All patients had squamous cell carcinoma. Induction chemotherapy consisted of 3–4 cycles every 3 weeks of docetaxel (day 1.70 mg/m2) and cisplatin (day 1.75 mg/m2). Radiation therapy (RT) was started with in 10 weeks of the last cycle of chemotherapy, and it was administered 5 days per week. It was given in daily fractions of (1.8) Grays (Gy) of 2 Gy and the total dose to the primary tumor was 70–74 Gy. Neck dissection was reserved for residual disease after definitive radiotherapy. Overall survival, recurrent free survival, and locoregional control were calculated using the Kaplan–Meier method. Twenty one patients with an unknown primary cancer underwent induction chemotherapy and radiotherapy. After induction chemotherapy, 6 patients achieved CR and 8 patients achieved PR. The overall response rate after radiation, was 90.4 % (19 of 21 patients). Neutropenia and infection were the most common grade 3–4 adverse event during induction chemotherapy. Mucositis and dermatitis were the most common grade 3–4 toxicities during radiotherapy. With a median follow-up of 50.6 months, the estimated 2 years OS rates were 71 ± 6 %, respectively. The median OS was 42 months (95 % confidence interval CI 8–65 months). The recurrent-free survival rate at 2 years was 57 %, respectively. In the patients with responder to induction chemotherapy, superior relapse free survival and overall survival rate observed. No occurrence of primary cancer was observed during the follow-up period. Induction chemotherapy followed RT for unknown primarycancer has provided good overall and disease-free survival in all the patients with anacceptable rate of complications. The use of induction chemotherapy and radiationtherapy for more advanced disease led to good clinical results with reasonable toxicities. © 2014, Association of Otolaryngologists of India.
引用
收藏
页码:74 / 78
页数:4
相关论文
共 50 条
  • [1] Cervical lymph node metastases of squamous cell carcinoma from an unknown primary
    Jereczek-Fossa, BA
    Jassem, J
    Orecchia, R
    CANCER TREATMENT REVIEWS, 2004, 30 (02) : 153 - 164
  • [2] Induction Docetaxel-Cisplatin Followed by Extended-field Radiotherapy in Patients with Cervical Metastases from Unknown Primary Carcinoma
    Perri, Francesco
    Ionna, Franco
    Muto, Paolo
    Buonerba, Carlo
    Scarpati, Giuseppina Della Vittoria
    Bosso, Davide
    Fulciniti, Franco
    Daponte, Antonio
    Argenone, Angela
    Sandomenico, Fabio
    Di Lorenzo, Giuseppe
    Caponigro, Francesco
    ANTICANCER RESEARCH, 2013, 33 (03) : 1135 - 1139
  • [3] CERVICAL LYMPH-NODE METASTASES FROM AN UNKNOWN PRIMARY
    NORDSTROM, DG
    TEWFIK, HH
    LATOURETTE, HB
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1979, 5 (01): : 73 - 76
  • [4] Combined surgery and postoperative radiotherapy for cervical lymph node metastases from an unknown primary tumour
    Strojan, P
    Anicin, A
    RADIOTHERAPY AND ONCOLOGY, 1998, 49 (01) : 33 - 40
  • [5] Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer
    Madani, Indira
    Vakaet, Luc
    Bonte, Katrien
    Boterberg, Tom
    De Neve, Wilfried
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (04): : 1158 - 1166
  • [6] CERVICAL LYMPH-NODE METASTASES FROM AN UNKNOWN PRIMARY TUMOR
    PACINI, P
    OLMI, P
    CELLAI, E
    CHIAVACCI, A
    ACTA RADIOLOGICA ONCOLOGY, 1981, 20 (05): : 311 - 314
  • [7] Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: Retrospective analysis of 113 patients
    Beldi, Debora
    Jereczek-Fossa, Barbara A.
    D'Onofrio, Alberto
    Gambaro, Giuseppina
    Fiore, Maria Rosaria
    Pia, Francesco
    Chiesa, Fausto
    Orecchia, Roberto
    Krengli, Marco
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04): : 1051 - 1058
  • [8] Predictive factors in patients with cervical lymph node metastases in unknown primary tumours
    Hauswald, H.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 90 - 90
  • [9] Role of radiotherapy in the treatment of cervical lymph node metastases from unknown primary site: results of a retrospective analysis of 113 patients
    Beldi, D.
    Jereczek-Fossa, B.
    D'onofrio, A.
    Orecchia, R.
    Krengli, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 313 - 313
  • [10] Therapy of cervical lymph node metastases of unknown primary tumor
    Ernst-Stecken, A
    Grabenbauer, GG
    Sauer, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S162 - S162